Transparency in clinical trials is continually changing, and to stay on top of the news, TrialAssure brings a weekly round-up of some of the key stories surrounding disclosures in clinical trials. This week’s stories are as follows:
Health Canada brings forward 5 transparency proposals – Raps.org
In support of an ongoing effort to increase transparency, Health Canada intends to implement five proposals related to prescription drugs and biologics by October 1, 2018. The proposals come from a division within Health Canada—the Health Products and Food Branch (HPFB)—as part of two 2015 transparency initiatives for drugs, biologics and medical devices.
Read the full article here.
Adherence to registration of clinical trials analyzed – Trials Journal
After reviewing 6,869 research reports, a new report in Trials found that adherence to ICMJE’s prospective registration policy is less than adequate across the board. This conclusion was drawn based on the identification of the frequency of registrations occurring after potential observation of primary outcome data among trials published in the highest-impact journals associated with professional medical societies in the United States.
Read the full study here.
Otsuka taps TrialAssure – Outsourcing-Pharma
Otsuka Pharmaceutical is partnering with TrialAssure to establish a clinical trial transparency management system in its drug development pipeline.
Read the news here.
